Immunotherapy Created 2026-10-31 Updated 2026-11-05
Immunotherapy modifies or uses immune responses to affect disease. Strategies can enhance a response, suppress it or direct it toward a particular target. The umbrella term therefore does not mean that every treatment simply increases immunity.
Maartje W. Rohaan Created 2026-10-20 Updated 2026-11-05
Researcher in immunotherapy. Rohaan and collaborators compared tumor-infiltrating lymphocyte therapy with ipilimumab in advanced melanoma, directly testing alternative treatment strategies rather than inferring benefit from immune activity alone.[ref]
The typical childhood picture is Sydenham's chorea: irregular involuntary movements, impaired sustained voluntary actions, variable weakness and emotional disturbance. A hypothetical schoolchild might gradually become unusually clumsy, drop utensils, spill drinks and produce deteriorating handwriting. Unpredictable movements pass between the face, trunk and limbs, giving facial grimaces and an unsteady gait. The chorea may be asymmetric. Asking the child to maintain a handgrip can reveal alternating tightening and relaxation; an outstretched hand or protruded tongue may not remain still. These are examples of motor impersistence, not wilful disobedience. Speech and feeding can become difficult. Marked weakness may accompany severe chorea. Anxiety or emotional lability may be conspicuous. This is a pattern to look for, not a claim that the unspecified person in the question has any particular finding.[ref][ref]
An 1867 account would associate childhood chorea with the period around puberty, preceding “rheumatism”, fright and general debility. It might also investigate supposed peripheral irritants such as intestinal parasites. These explanations were not equally secure. Fright could precede or aggravate the visible movements without establishing their fundamental cause, and finding intestinal parasites did not prove that they caused the chorea. Contemporary discussion already recognized spontaneous recovery and disputed whether reported drug cures exceeded it.[ref]
A reasonable historical treatment outline begins with quiet surroundings, rest, adequate food, assistance with feeding and protection from injury in violent chorea. Genuine associated illness, including anaemia, required attention. Preparations of iron were common “tonics”; other remedies of the period included experimental mineral drugs. Their use should be reported as historical practice, not as an effective modern recipe. A recovery after weeks of treatment does not distinguish a pharmacological effect from the natural course of Sydenham's chorea.[ref]
Modern correction: the usual cause of the classic childhood syndrome is an immune-mediated consequence of preceding group A streptococcal infection, not fright, moral weakness or an intestinal “irritation”. Sydenham's chorea, named after Thomas Sydenham, can be the sole late manifestation of acute rheumatic fever. Assess for carditis even without an obvious heart murmur: echocardiography can reveal otherwise silent valve disease. Treat residual group A streptococcal infection and institute appropriate secondary antibiotic prophylaxis; these measures prevent further attacks rather than instantly stopping established movements.[ref]
Management varies with function. Mild Sydenham's chorea may need supportive measures alone. When eating, walking or self-care is substantially impaired, specialist care can add a movement-suppressing drug such as carbamazepine. Severe disease may justify corticosteroid treatment; very severe or refractory disease may need further specialist immunotherapy. Evidence and practice differ between guidelines, and improvement is not necessarily immediate. sodium valproate is another option in selected circumstances, but its reproductive and other adverse effects are material limitations.[ref][ref] Atypical onset, progression, exposure to relevant drugs or other focal neurological signs calls for reconsideration of the cause of the chorea, rather than automatic assignment to acute rheumatic fever.
Richard A. Morgan Created 2026-10-20 Updated 2026-11-05
Researcher in immunotherapy. Richard A. Morgan and collaborators reported a serious adverse event after engineered T-cell administration, documenting why target recognition must be assessed in healthy tissues as well as tumours.[ref]